Crizanlizumab for COVID-19: real-time analysis of 2 studies

Download Image

Post

c19early.org

Crizanlizumab for COVID-19

2 studies with 463 patients

Serious outcome risk

Crizanlizumab

Control

COVID-19 Crizanlizumab studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (2)−29%

Mortality (1)−33%

RCTs (2)−29%

Late (2)−29%

00.511.5+

← Crizanlizumab
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


	Covid Analysis	Meta-analysis of crizanlizumab studies
	Meta-analysis of crizanlizumab studies
Aug 31 2023	Solomon et al., Circulation, doi:10.1161/CIRCULATIONAHA.123.065190	Effect of the P-Selectin Inhibitor Crizanlizumab on Survival Free of Organ Support in Patients Hospitalized for COVID-19: A Randomized Controlled Trial
	33% higher mortality (p=0.24) and 43% worse results (p=0.16). RCT 422 hospitalized COVID-19 patients showing no significant difference in mortality or organ support-free days with crizanlizumab, a P-selectin inhibitor. There was a trend towards increased mortality with crizanlizumab. The study was s..
Dec 31 2021	Leucker et al., JACC: Basic to Translational Science, doi:10.1016/j.jacbts.2021.09.013	Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19
	35% lower hospital discharge (p=0.16). RCT 54 hospitalized COVID-19 patients showing crizanlizumab treatment reduced soluble P-selectin levels, increased D-dimer levels, and decreased prothrombin fragment 1.2 compared to placebo. There were no significant differences in inflam..